Skip to main content
SpringerLink
Log in

Evolving strategies to overcome endocrine resistance in breast cancer

  • review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Endocrine therapies targeting estrogen action decrease mortality from breast cancer, but their efficacy is limited by intrinsic and acquired therapeutic resistance. Various mechanisms can contribute to insensitivity toward endocrine treatment in hormone receptor-positive breast cancer patients. Definition of the specific genetic lesions and molecular processes that determine clinical endocrine resistance is still incomplete but recently tremendous advances have been made. In this short review the latest strategies to overcome endocrine resistance will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beatson G. On the treatment of inoperable cases of carcinoma of the mammary: suggestions for a new method of treatment with illustrative cases. Lancet. 1896;2(104–107):162–5.

    Article  Google Scholar 

  2. Ghayad SE, et al. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010;126(2):545–62.

    Article  CAS  PubMed  Google Scholar 

  3. Creighton CJ, et al. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008;68(18):7493–501.

    Article  CAS  PubMed  Google Scholar 

  4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.

    Article  Google Scholar 

  5. Forbes JF, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53.

    Article  PubMed  Google Scholar 

  6. Dowsett M, et al. Growth factor signalling and response to endocrine therapy: the royal marsden experience. Endocr Relat Cancer. 2005;12(Suppl. 1):S113–7.

    Article  CAS  PubMed  Google Scholar 

  7. Gutierrez MC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005;23(11):2469–76.

    Article  CAS  PubMed  Google Scholar 

  8. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9(8):576–86.

    Article  CAS  PubMed  Google Scholar 

  9. Klinge CM, et al. Estrogen response element sequence impacts the conformation and transcriptional activity of estrogen receptor alpha. Mol Cell Endocrinol. 2001;174(1–2):151–66.

    Article  CAS  PubMed  Google Scholar 

  10. Kushner PJ, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000;74(5):311–7.

    Article  CAS  PubMed  Google Scholar 

  11. Smith CL, O’Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 2004;25(1):45–71.

    Article  CAS  PubMed  Google Scholar 

  12. Jakacka M, et al. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem. 2001;276(17):13615–21.

    CAS  PubMed  Google Scholar 

  13. Gruber CJ, et al. Production and actions of estrogens. N Engl J Med. 2002;346(5):340–52.

    Article  CAS  PubMed  Google Scholar 

  14. Schiff R, et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004;10(1 Pt 2):S331–6.

    Article  CAS  PubMed  Google Scholar 

  15. Lopez-Tarruella S, Schiff R. The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clin Cancer Res. 2007;13(23):6921–5.

    Article  CAS  PubMed  Google Scholar 

  16. Wilson GR, et al. Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer. 2006;95(10):1410–4.

    Article  CAS  PubMed  Google Scholar 

  17. Lombardo LJ, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658–61.

    Article  CAS  PubMed  Google Scholar 

  18. Morgan L, et al. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther. 2009;8(16):1550–8.

    Article  CAS  PubMed  Google Scholar 

  19. De Laurentiis M, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005;11(13):4741–8.

    Article  CAS  PubMed  Google Scholar 

  20. Pietras RJ, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995;10(12):2435–46.

    CAS  PubMed  Google Scholar 

  21. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res. 2007;13(7):1950–4.

    Article  CAS  PubMed  Google Scholar 

  22. Osborne CK, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011;17(5):1147–59.

    Article  CAS  PubMed  Google Scholar 

  23. Cristofanilli M, et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010;16(6):1904–14.

    Article  CAS  PubMed  Google Scholar 

  24. Kaufman B, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–37.

    Article  CAS  PubMed  Google Scholar 

  25. Johnston S, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–46.

    Article  CAS  PubMed  Google Scholar 

  26. LoPiccolo J, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008;11(1–2):32–50.

    Article  CAS  PubMed  Google Scholar 

  27. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol. 2009;10(12):1179–87.

    Article  CAS  PubMed  Google Scholar 

  28. Baselga J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630–7.

    Article  CAS  PubMed  Google Scholar 

  29. Bachelot TCB, Cropet C, Guastalla J-P, Ferrero J-M, Leger-Falandry C, Soulie P, et al. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Cancer Res. 2010;70(24):Abst. S1–6.

    Article  Google Scholar 

  30. Baselga J, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9.

    Article  CAS  PubMed  Google Scholar 

  31. Knowlden JM, et al. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance. Breast Cancer Res Treat. 2008;111(1):79–91.

    Article  CAS  PubMed  Google Scholar 

  32. Rosenzweig SA, Atreya HS. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol. 2011;80(8):1115–24.

    Article  Google Scholar 

  33. Tolcher AW, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009;27(34):5800–7.

    Article  CAS  PubMed  Google Scholar 

  34. Kaufman PA, Ferrero JM, Bourgeois H, Kennecke H, De Boer R, Jacot W, et al. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res. 2010;70(76s):S1–4.

    Google Scholar 

  35. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26(37):5310–8.

    Article  CAS  PubMed  Google Scholar 

  36. Huang X, et al. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res. 2009;69(21):8403–11.

    Article  CAS  PubMed  Google Scholar 

  37. Yardley DA, Ismail-Khan R, Klein PM. Entinostat, a novel histone deacetylase inhibitor, added to exemestane improves PFS in advanced breast cancer in a randomized, phase II, double-blind study. Cancer Res. 2011;70(24):PD01–04.

    Google Scholar 

  38. Yue W, et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol. 2007;106(1–5):102–10.

    Article  CAS  PubMed  Google Scholar 

  39. Kato K, et al. Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A. 1992;89(14):6403–7.

    Article  CAS  PubMed  Google Scholar 

  40. Johnston SR, et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat. 2008;110(2):327–35.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Brustgesundheitzentrum Tirol, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria

    Michael Hubalek M.D., Christine Brunner M.D. & Christian Marth M.D.

Authors
  1. Michael Hubalek M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Brunner M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Marth M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Hubalek M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hubalek, M., Brunner, C. & Marth, C. Evolving strategies to overcome endocrine resistance in breast cancer. memo 5, 105–109 (2012). https://doi.org/10.1007/s12254-012-0003-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-012-0003-6

Keywords

Search

Navigation